Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS Looks To Expand Its Oncology Reach With Mirati Buyout

09 Oct 2023

• By Andrew McConaghie

BMS

Related Content

FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement

05 Sep 2023

Roche’s Divarasib Shows Competitive Data As Monotherapy In KRAS

24 Aug 2023

BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition

03 Jun 2022

Related Companies

Mirati Therapeutics, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Amgen, Inc.

Sanofi

MyoKardia, Inc.

Turning Point Therapeutics Inc.

Additional Topics

Deals M & A Commercial Companies Strategy Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.